Piloplex, a new long-acting pilocarpine polymer salt. A: Long-term study.
Thirty eyes of 15 patients with open-angle glaucoma were followed up for a period of up to  1 year while being treated with Piloplex eye drops containg a new long-acting pilocarpine polymer salt. Average morning intraocular pressure (IOP) values during treatment with pilocarpine hydrochloride administered 4 times daily was 20.5 mmHg. Average morning IOP values during Piloplex medication administered only twice daily were 19.8 to 18.2 mmHg (range of averages on 14 sessions). These findings indicate the lower average pressure during Piloplex medication and show its prolonged hypotensive effect. Both medications contained an equivalent total daily amount of pilocarpine. Throughout the 1-year study period no adverse side effects were reported, and only 1 patient complained of local sensitivity reaction. Visual disturbances characteristic of pilocarpine eye drops were reduced from 3 times a day on pilocarpine hydrochloride 4 times daily to once a day on Piloplex twice daily.
D000368:Aged; D002940:Circadian Rhythm; D003692:Delayed-Action Preparations; D004341:Drug Evaluation; D004655:Emulsions; D005260:Female; D005500:Follow-Up Studies; D005901:Glaucoma / Q000188:drug therapy*; D006801:Humans; D066298:In Vitro Techniques; D007429:Intraocular Pressure / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D009883:Ophthalmic Solutions; D010862:Pilocarpine / Q000008:administration & dosage / Q000627:therapeutic use*; D011108:Polymers / Q000008:administration & dosage / Q000627:therapeutic use*; D013997:Time Factors
D003692:Delayed-Action Preparations; D004655:Emulsions; D009883:Ophthalmic Solutions; D011108:Polymers; D010862:Pilocarpine; C018639:Piloplex